The data came from a phase 3 trial that enrolled 29,960 participants across 119 sites in the U.S. and Mexico. Novavax said it recruited participants from the communities and demographic groups most affected by COVID-19.
Should the vaccine be cleared by the FDA, Novavax is ready to manufacture 150 million doses each month by the end of 2021.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.